Therefore, FXR agonists are promising for the treatment of non-alcoholic fatty liver disease (NAFLD), dyslipidemia and type 2 diabetes7, 8, 9, 10. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.